WuXi Biologics has been recognized by Morningstar Sustainalytics as a leading ESG (environmental, social and governance) company in 2025, for the fifth year running. Ranked in the top 1% of companies in the pharmaceutical sector, this distinction underlines the company's pioneering role in sustainable and responsible practices. The company was judged on key elements of the sector. Sustainalytics analyzes the material risks faced by companies in their sector, in this case biopharmaceuticals. The assessment also looks at how WuXi Biologics manages these risks, notably through sustainable and responsible practices. The Chinese specialist was also awarded the " CDMO Leadership Award ", for the 8th year running (CDMOs are organizations responsible for the outsourced manufacture of drug substances, and the innovation and development process preceding manufacture). The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Leader. For the 2025 edition, more than 200 CDMOs were assessed on the basis of an independent study, and WuXi came out on top again. A few months ago, the Dow Jones Sustainability 2024 index rewarded the company.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, said, "We are honored to receive this distinction again, which reflects our ongoing commitment to sustainability." The company has also distinguished itself through notable achievements, such as its EcoVadis Platinum Medal (the most widely acclaimed sustainability and corporate social responsibility rating organization, with over 130,000 companies assessed worldwide and present in the Vintage FPCI Altaroc Odyssey 2021), and its MSCI AAA rating (the highest rating that rewards a company's management of ESG risks and opportunities).
WuXi Biologics implements innovative solutions to reduce its ecological footprint while supporting its partners in their ESG commitments. WuXi Biologics is listed in the United Nations Global Compact as an example of sustainable development, and is included in the FTSE4Good and Hang Seng ESG 50 indices.
